Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Review Article

Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction

Author(s): Ghulam Murtaza*, Adeel Siddiqui and Izhar Hussain

Volume 19, Issue 11, 2018

Page: [1079 - 1087] Pages: 9

DOI: 10.2174/1389203719666180709103020

Price: $65

Abstract

Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.

Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy